Kutaner Lupus erythematodes

Lernziele

Kenntnisse über folgende Aspekte des kutanen Lupus erythematodes:

• Epidemiologie

• Ätiologie

• Klassifikation

• Diagnostik

• Aktivitätsscore (RCLASI)

• ACR-Kriterien

• Therapie

• Prognose

• Lebensqualität

• Literatur

• 1 Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110-2121
• 2 Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin 2002; 20: 373-385
• 3 Kuhn A, Ruland V, Bonsmann G. Hautmanifestationen des Lupus erythematodes: Klinik und Therapie. Z Rheumatol 2011; 70: 213-226
• 4 Tebbe B, Orfanos CE. Prognosis of Cutaneous Lupus Erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, eds. Cutaneous Lupus Erythematosus. Berlin: Springer; 2004: 187-204
• 5 Gronhagen CM, Fored CM, Granath F et al. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol 2011; 164: 1335-1341
• 6 Kuhn A, Haust M, Bonsmann G. Klinik und Therapie von SLE Hautmanifestationen. In: Aringer M, Aufricht C, Berger SP. Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. Bremen: Uni-Med Verlag; 2011: 56-63
• 7 Gilliam JN. The cutaneous signs of lupus erythematosus. Cont Educ Fam Phys 1977; 6: 34-70
• 8 Popovic K, Nyberg F, Wahren-Herlenius M. A serology-based approach combined with clinical examination of 125 Ro/SSA-positive patients to define incidence and prevalence of subacute cutaneous lupus erythematosus. Arthritis Rheum 2007; 56: 255-264
• 9 Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev 2005; 4: 253-263
• 10 Sontheimer RD, Kovalchick P. Cutaneous manifestations of rheumatic diseases: lupus erythematosus, dermatomyositis, scleroderma. Dermatol Nurs 1998; 10: 81-95
• 11 Kuhn A, Bein D, Bonsmann G. The 100th anniversary of lupus erythematosus tumidus. Autoimmun Rev 2009; 8: 441-448
• 12 Tebbe B, Orfanos CE. Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus 1997; 6: 96-104
• 13 Kanda N, Tsuchida T, Watanabe T et al. Clinical features of systemic lupus erythematosus in men. Characteristics of the cutaneous manifestations. Dermatology 1996; 193: 6-10
• 14 Kuhn A, Aberer E, Barde C et al. Leitlinien Kutaner Lupus Erythematodes (Entwicklungsstufe 1). In: Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W, Hrsg. Dermatologische Qualitätssicherung: Leitlinien und Empfehlungen. Berlin: ABW Wissenschaftsverlag GmbH; 2009: 214-257
• 15 Kuhn A, Ruland V, Bonsmann G. Photosensitivity, phototesting, and photoprotection in cutaneous lupus erythematosus. Lupus 2010; 19: 1036-1046
• 16 Kuhn A, Sonntag M, Richter-Hintz D et al. Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol 2001; 45: 86-95
• 17 Callen JP. Drug-induced subacute cutaneous lupus erythematosus. Lupus 2010; 19: 1107-1111
• 18 Gallego H, Crutchfield CE 3rd, Lewis EJ et al. Report of an association between discoid lupus erythematosus and smoking. Cutis 1999; 63: 231-234
• 19 Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000; 42: 983-987
• 20 Rahman P, Gladman DD, Urowitz MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998; 25: 1716-1719
• 21 Piette EW, Foering KP, Chang AY et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol 2011; 148: 317-322
• 22 Kreuter A, Gaifullina R, Tigges C et al. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch Dermatol 2009; 145: 244-248
• 23 Ueki H. Koebner phenomenon in lupus erythematosus with special consideration of clinical findings. Autoimmun Rev 2005; 4: 219-223
• 24 Kuhn A, Böhm M, Luger TA. Tissue injury and the skin. In: Lahita R, Tsokos G, Koike T, eds. Systemic Lupus Erythematosus. New York: Elsevier; 2010: 475-490
• 25 Lee-Kirsch MA, Gong M, Schulz H et al. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet 2006; 79: 731-737
• 26 Racila DM, Sontheimer CJ, Sheffield A et al. Homozygous single nucleotide polymorphism of the complement C1QA gene is associated with decreased levels of C1q in patients with subacute cutaneous lupus erythematosus. Lupus 2003; 12: 124-132
• 27 Trendelenburg M, Schifferli JA. Apoptosis and C1q: possible explanations for the pathogenesis of systemic lupus erythematosus. Z Rheumatol 2000; 59: 172-175
• 28 Kuhn A, Ruzicka T. Classification of Cutaneous Lupus Erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, eds. Cutaneous Lupus Erythematosus. Berlin: Springer; 2004: 53-58
• 29 Kuhn A, Gensch K, Stander S et al. Kutaner Lupus erythematodes. Teil 1: Klinik und Klassifikation. Hautarzt 2006; 57: 251-267
• 30 Kuhn A, Sticherling M, Bonsmann G. Klinische Manifestationen des kutanen Lupus erythematodes: Teil 1. J Dtsch Dermatol Ges 2007; 5: 1124-1137
• 31 Ting W, Stone MS, Racila D et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus 2004; 13: 941-950
• 32 Aydogan K, Karadogan S, Balaban Adim S et al. Lupus erythematosus associated with erythema multiforme: report of two cases and review of the literature. J Eur Acad Dermatol Venereol 2005; 19: 621-627
• 33 Kuhn A, Richter-Hintz D, Oslislo C et al. Lupus erythematosus tumidus – a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 2000; 136: 1033-1041
• 34 Schmitt V, Meuth AM, Amler S et al. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus. Br J Dermatol 2010; 162: 64-73
• 35 Kuhn A, Sonntag M, Richter-Hintz D et al. Phototesting in lupus erythematosus tumidus-review of 60 patients. Photochem Photobiol 2001; 73: 532-536
• 36 Vassileva S. Bullous systemic lupus erythematosus. Clin Dermatol 2004; 22: 129-138
• 37 Lee LA. Transient autoimmunity related to maternal autoantibodies: neonatal lupus. Autoimmun Rev 2005; 4: 207-213
• 38 Kuhn A, Gensch K, Stander S et al. Kutaner Lupus erythematodes. Teil 2: Diagnostik und Therapie. Hautarzt 2006; 57: 345-348
• 39 David-Bajar KM, Davis BM. Pathology, immunopathology, and immunohistochemistry in cutaneous lupus erythematosus. Lupus 1997; 6: 145-157
• 40 Baltaci M, Fritsch P. Histologic features of cutaneous lupus erythematosus. Autoimmun Rev 2009; 8: 467-473
• 41 Kuhn A, Sonntag M, Ruzicka T et al. Histopathologic findings in lupus erythematosus tumidus: review of 80 patients. J Am Acad Dermatol 2003; 48: 901-908
• 42 Jerdan MS, Hood AF, Moore GW et al. Histopathologic comparison of the subsets of lupus erythematosus. Arch Dermatol 1990; 126: 52-55
• 43 Kuhn A, Sontheimer RD. Cutaneous lupus erythematosus: molecular and cellular basis of clinical findings. Curr Dir Autoimmun 2008; 10: 119-140
• 44 Albrecht J, Taylor L, Berlin JA et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125: 889-894
• 45 Kuhn A, Meuth AM, Bein D et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol 2010; 163: 83-92
• 46 Wahie S, McColl E, Reynolds NJ et al. Measuring disease activity and damage in discoid lupus erythematosus. Br J Dermatol 2010; 162: 1030-1037
• 47 Abdel-Aziz K, Goodfield M. Evaluation of the Cutaneous Lupus Activity and Severity Score in the assessment of lupus erythematosus skin disease. Br J Dermatol 2008; 158: 181-182
• 48 Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277
• 49 Albrecht J, Berlin JA, Braverman IM et al. Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. Lupus 2004; 13: 839-849
• 50 Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: Update of therapeutic options Part I. J Am Acad Dermatol 2011; 65: e179-193
• 51 Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: Update of therapeutic options Part II. J Am Acad Dermatol 2011; 65: e195-213
• 52 Hampton PJ, Farr PM, Diffey BL et al. Implication for photosensitive patients of ultraviolet A exposure in vehicles. Br J Dermatol 2004; 151: 873-876
• 53 Faurschou A, Wulf HC. The relation between sun protection factor and amount of suncreen applied in vivo. Br J Dermatol 2007; 156: 716-719
• 54 Kuhn A, Gensch K, Haust M et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol 2011; 64: 37-48
• 55 Lowe G, Henderson CL, Grau RH et al. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2011; 164: 465-472
• 56 Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009; CD002954
• 57 Sardy M, Ruzicka T, Kuhn A. Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res 2009; 301: 93-98
• 58 Kuhn A, Gensch K, Haust M et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 2011; 65: 54-64
• 59 Avgerinou G, Papafragkaki DK, Nasiopoulou A et al. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 2012; 26: 762-767
• 60 Wulf HC, Ullman S. Discoid and subacute lupus erythematosus treated with 0.5% R-salbutamol cream. Arch Dermatol 2007; 143: 1589-1590
• 61 Jemec GB, Ullman S, Goodfield M et al. A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus. Br J Dermatol 2009; 161: 1365-1370
• 62 Kuhn A, Becker-Wegerich PM, Ruzicka T et al. Successful treatment of discoid lupus erythematosus with argon laser. Dermatology 2000; 201: 175-177
• 63 Wenzel J, Bieber T, Uerlich M et al. Systemische Therapie des kutanen Lupus erythematodes. J Dtsch Dermatol Ges 2003; 1: 694-704
• 64 Ochsendorf FR. Einsatz von Antimalariamitteln in der Dermatologie. J Dtsch Dermatol Ges 2010; 8: 829-844
• 65 Polet H. The effects of lysosomotropic amines on protein degradation, migration of nonhistone proteins to the nucleus, and cathepsin D in lymphocytes. J Cell Physiol 1985; 122: 415-423
• 66 Vazquez-Del MM, Munoz-Valle JF, Santos A et al. Evaluation of lipid profile, macular toxicity and clinical manifestations according to APO E genotype in systemic lupus erythematosus and rheumatoid arthritis patients treated with chloroquine. Scand J Rheumatol 2002; 31: 32-37
• 67 Wenzel J, Brahler S, Bauer R et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 2005; 153: 157-162
• 68 Klein A, Vogt T, Wenzel SM et al. Cyclosporin combined with methotrexate in two patients with recalcitrant subacute cutaneous lupus erythematosus. Australas J Dermatol 2011; 52: 43-47
• 69 Al-Mutairi N, Rijhwani M, Nour-Eldin O. Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy. J Dermatol 2005; 32: 482-486
• 70 Ruzicka T, Sommerburg C, Goerz G et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992; 127: 513-518
• 71 Bacman D, Kuhn A, Ruzicka T. Dapsone and Retinoids. In: Kuhn A, Lehmann P, Ruzicka T, eds. Cutaneous Lupus Erythematosus. Berlin: Springer; 2004: 373-390
• 72 Kuhn A, Patsinakidis N, Luger TA. Alitretinoin for cutaneous lupus erythematosus. J Am Acad Dermatol 2012; 67: e123-126
• 73 Hall RP, Lawley TJ, Smith HR et al. Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med 1982; 97: 165-170
• 74 Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 1986; 172: 214-217
• 75 Ujiie H, Shimizu T, Ito M et al. Lupus erythematosus profundus successfully treated with dapsone: review of the literature. Arch Dermatol 2006; 142: 399-401
• 76 Walsh M, James M, Jayne D et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007; 2: 968-975
• 77 Boehm I, Bieber T. Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 2001; 137: 235-236
• 78 Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001; 45: 142-144
• 79 Schanz S, Ulmer A, Rassner G et al. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002; 147: 174-178
• 80 Hanjani NM, Nousari CH. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol 2002; 138: 1616-1618
• 81 Pisoni CN, Obermoser G, Cuadrado MJ et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 2005; 23: 393-396
• 82 Kreuter A, Tomi NS, Weiner SM et al. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol 2007; 156: 1321-1377
• 83 Cortes-Hernandez J, Torres-Salido M, Castro-Marrero J et al. Thalidomide in the treatment of refractory cutaneous lupus: prognostic factors of clinical outcome. Br J Dermatol 2012; 166: 616-623
• 84 Braunstein I, Goodman NG, Rosenbach M et al. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: Histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol 2012; 66: 571-582
• 85 Shah A, Albrecht J, Bonilla-Martinez Z et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol 2009; 145: 303-306
• 86 Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol 2007; 56: e55-79
• 87 Navarra SV, Guzman RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-731
• 88 Tebbe B, Orfanos CE. Prognosis of Cutaneous Lupus Erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, eds. Cutaneous Lupus Erythematosus. Berlin: Springer; 2004: 187-202
• 89 Klein R, Moghadam-Kia S, Taylor L et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol 2011; 64: 849-858
• 90 Kuhn A, Sticherling M. Lupus erythematodes. In: Plewig G, Landthaler M, Burgdorf W, Ruzicka D. Braun-Falco’s Dermatologie, Venerologie und Allergologie. 6. Aufl. Heidelberg: Springer; 2012: 866-882
• 91 Izmirly PM et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126: 76-82
• 92 Petri M, Orbai AM, Alarcon GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-2686